top of page

First dosing of Pfizer DART candidate in phase 1 trial triggers $2m milestone payment to MacroGenics

MacroGenics announced that its collaboration partner, Pfizer, has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART, platform.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page